GO:0051791 medium-chain fatty acid metabolic process: Energy Pathway, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0051791 describes the chemical reactions and pathways involving medium-chain fatty acids (MCFAs), defined as fatty acids with aliphatic tails of 6 to 12 carbons.
• MCFAs are rapidly oxidized for energy and can enter mitochondria independently of the carnitine shuttle in liver and kidney, but not in heart and skeletal muscle.
• MCFA metabolism is implicated in kidney fibrosis, obesity, and metabolic disorders, and is a target for therapeutic interventions such as triheptanoin.
• Key enzymes include ACSM3, which is essential for tubular MCFA metabolism and protection against kidney fibrosis.
• MCFA metabolic pathways are regulated by pH and fermentation conditions in environmental and industrial contexts.
• CRISPR-based models (knockout, knock-in, overexpression) enable precise dissection of MCFA metabolism genes in health and disease.
Description
Medium-chain fatty acid metabolic process (GO:0051791) encompasses the biochemical reactions and pathways that convert medium-chain fatty acids (MCFAs) into energy and other metabolites. MCFAs are defined as fatty acids with aliphatic tails containing 6 to 12 carbons, such as caproic acid (C6), caprylic acid (C8), capric acid (C10), and lauric acid (C12). This process is fundamental to cellular energy homeostasis and has broad implications for metabolic diseases, kidney function, and even industrial biotechnology. Researchers study this term to understand how MCFAs are oxidized, synthesized, and regulated, and to identify therapeutic targets for conditions like obesity and fibrosis.
medium-chain fatty acid metabolic process At A Glance
| GO ID | GO:0051791 |
|---|---|
| GO term | medium-chain fatty acid metabolic process |
| Ontology | biological_process |
| Synonym | medium chain fatty acid metabolic process; medium chain fatty acid metabolism; medium-chain fatty acid metabolism |
| Major function | Energy production, lipid homeostasis, and metabolic regulation |
| Cellular location | Mitochondria, peroxisomes, cytoplasm |
| Key enzymes | ACSM3, acyl-CoA dehydrogenases, thiolases |
| Related pathways | Fatty acid beta-oxidation, ketogenesis, lipogenesis |
What Is GO:0051791?
GO:0051791 is a biological process term defined as the chemical reactions and pathways involving a medium-chain fatty acid, where a medium-chain fatty acid has an aliphatic tail containing 6 to 12 carbons. This includes both the breakdown (oxidation) and synthesis of MCFAs, as well as their interconversion and utilization in energy metabolism.
Why Is medium-chain fatty acid metabolic process Important in Cell Biology?
Medium-chain fatty acid metabolism is critical for energy production, especially during fasting or ketogenic states, and its dysregulation is linked to metabolic disorders, kidney fibrosis, and obesity. Understanding this process can inform therapeutic strategies such as triheptanoin for metabolic diseases and guide biotechnological production of MCFAs.
• Provides rapid energy source independent of carnitine shuttle in liver and kidney.
• Dysregulation contributes to kidney fibrosis via ACSM3 deficiency.
• MCFAs are used in obesity treatment due to their effects on energy expenditure.
• Triheptanoin, an MCFA, is approved for long-chain fatty acid oxidation disorders.
• MCFA production is relevant for industrial fermentation and waste valorization.
• MCFA metabolism intersects with mitochondrial function and oxidative stress.
• Genetic variants in MCFA enzymes may influence metabolic disease risk.
• MCFAs serve as signaling molecules and substrates for ketone body production.
• Research on MCFA metabolism informs personalized nutrition and metabolic therapies.
• CRISPR screens can identify novel regulators of MCFA metabolic pathways.
What Happens During medium-chain fatty acid metabolic process?
Uptake and Activation of MCFAs
In simple terms: MCFAs enter cells and are primed for breakdown.
Medium-chain fatty acids are taken up by cells and activated to acyl-CoA derivatives by acyl-CoA synthetases, such as ACSM3, which is specifically involved in medium-chain fatty acid metabolism in kidney tubular cells. This activation step is required for subsequent oxidation or synthesis pathways.
Mitochondrial Beta-Oxidation
In simple terms: MCFAs are burned for energy in mitochondria.
Once activated, medium-chain acyl-CoAs enter mitochondria and undergo beta-oxidation to generate acetyl-CoA, which feeds the TCA cycle. In liver and kidney, this process is independent of L-carnitine, whereas heart and skeletal muscle require carnitine for MCFA oxidation. This tissue-specific difference highlights the metabolic flexibility of MCFA utilization.
Ketogenesis and Energy Expenditure
In simple terms: MCFAs can be converted into ketone bodies, which fuel the brain and other tissues.
Excess acetyl-CoA from MCFA oxidation can be diverted to ketogenesis, producing beta-hydroxybutyrate and acetoacetate. This pathway is particularly active in the liver and contributes to the effects of MCFAs on energy expenditure and obesity management.
Synthesis and Interconversion of MCFAs
In simple terms: Cells can also build MCFAs from other molecules.
MCFAs can be synthesized through chain elongation of shorter fatty acids or by reverse beta-oxidation. In environmental and industrial settings, microbial fermentation produces MCFAs from organic waste, with pH and electron donors influencing the metabolic flux.
Regulation by pH and Fermentation Conditions
In simple terms: The environment can change how MCFAs are made or broken down.
In waste activated sludge fermentation, pH-dependent regulation shifts metabolic pathways toward medium-chain fatty acid synthesis, affecting the yield and profile of products. Similarly, electro-fermentation and thermal hydrolysis can enhance MCFA production from organic substrates.
Key Genes Involved in GO:0051791 medium-chain fatty acid metabolic process
The following genes and proteins are experimentally implicated in medium-chain fatty acid metabolic process.
| Gene | Major Role | Research Relevance |
|---|---|---|
| ACSM3 | Activates medium-chain fatty acids to acyl-CoA | Deficiency impairs MCFA metabolism and aggravates kidney fibrosis |
| ACADM | Catalyzes first step of mitochondrial beta-oxidation of medium-chain acyl-CoAs | Mutations cause MCAD deficiency, a fatty acid oxidation disorder |
| HADHA | Subunit of mitochondrial trifunctional protein, involved in beta-oxidation | Defects lead to long-chain fatty acid oxidation disorders |
| CPT1A | Carnitine palmitoyltransferase 1A, regulates entry of long-chain fatty acids into mitochondria | Not required for MCFA oxidation in liver/kidney but important for heart/muscle |
| CPT2 | Carnitine palmitoyltransferase 2, inner mitochondrial membrane enzyme | Defects cause carnitine palmitoyltransferase II deficiency |
| ACSL1 | Acyl-CoA synthetase long-chain family member 1 | May contribute to MCFA activation in some tissues |
| ACSM1 | Acyl-CoA synthetase medium-chain family member 1 | Involved in MCFA activation and metabolism |
| ACSM2A | Acyl-CoA synthetase medium-chain family member 2A | Kidney-specific MCFA activation |
| ACSM2B | Acyl-CoA synthetase medium-chain family member 2B | Liver-specific MCFA activation |
| ACSM4 | Acyl-CoA synthetase medium-chain family member 4 | Olfactory-specific MCFA metabolism |
| ACSM5 | Acyl-CoA synthetase medium-chain family member 5 | Potential role in MCFA metabolism |
| HADH | Hydroxyacyl-CoA dehydrogenase, beta-oxidation enzyme | Deficiency causes hyperinsulinism |
| ACAT1 | Acetyl-CoA acetyltransferase 1, thiolase | Involved in ketogenesis and isoleucine degradation |
| EHHADH | Enoyl-CoA hydratase/3-hydroxyacyl CoA dehydrogenase | Peroxisomal beta-oxidation of MCFAs |
| PPARA | Peroxisome proliferator-activated receptor alpha | Regulates fatty acid oxidation genes |
| SLC25A20 | Carnitine-acylcarnitine translocase | Required for carnitine-dependent fatty acid oxidation |
| TRIHEPTANOIN | Not a gene; triheptanoin is a synthetic MCFA triglyceride | Used for long-chain fatty acid oxidation disorders |
How Is medium-chain fatty acid metabolic process Regulated?
Medium-chain fatty acid metabolic process is regulated at multiple levels. In liver and kidney, MCFA oxidation occurs independently of L-carnitine, suggesting tissue-specific regulatory mechanisms. The expression of ACSM3 is critical for tubular MCFA metabolism, and its loss leads to kidney fibrosis, indicating tight regulation of this enzyme. Additionally, environmental factors such as pH and electron donor availability modulate microbial MCFA synthesis pathways. Hormonal and nutritional signals, including PPAR alpha activation, also influence MCFA oxidation rates.
medium-chain fatty acid metabolic process and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| ACSM3 | Kidney fibrosis | ACSM3 knockout mouse or kidney organoids |
| ACADM | Medium-chain acyl-CoA dehydrogenase deficiency | ACADM knockout cell lines and mouse models |
| HADHA | Long-chain fatty acid oxidation disorders | HADHA knockout iPSC-derived cardiomyocytes |
| PPARA | Obesity and metabolic syndrome | PPARA knockout or overexpression models |
| CPT2 | Carnitine palmitoyltransferase II deficiency | CPT2 mutant knock-in cells |
Kidney Fibrosis
Tubular ACSM3 deficiency impairs medium-chain fatty acid metabolism and aggravates kidney fibrosis, highlighting the role of MCFA metabolism in renal disease progression. This suggests that targeting MCFA metabolic pathways could be therapeutic for fibrosis.
Obesity and Metabolic Disorders
Medium-chain fatty acid metabolism influences energy expenditure and has implications for obesity treatment. Diets enriched in MCFAs can increase thermogenesis and fat oxidation, making them attractive for weight management.
Long-Chain Fatty Acid Oxidation Disorders
Triheptanoin, a medium-chain triglyceride, is approved for the treatment of long-chain fatty acid oxidation disorders, demonstrating the therapeutic potential of MCFA metabolism modulation.
From medium-chain fatty acid metabolic process-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does ACSM3 loss alter MCFA metabolism? | ACSM3 knockout cell line (e.g., HEK293 or kidney tubular cells) |
| Does a point mutation in ACADM affect enzyme activity? | ACADM point-mutation knock-in cells |
| Can overexpression of ACSM3 rescue fibrosis? | ACSM3 overexpression in kidney fibroblasts |
| What is the role of CPT1A in MCFA oxidation? | CPT1A knockout hepatocytes |
| Does triheptanoin improve metabolic flux? | Patient-derived fibroblasts with fatty acid oxidation defects |
| Identify novel regulators of MCFA metabolism | CRISPR library screening in metabolic cell models |
How to Study the medium-chain fatty acid metabolic process Process
| Method | What It Measures | Typical Application |
|---|---|---|
| 13C-MCFA tracing | Oxidation rate and metabolite incorporation | Assessing metabolic flux in cells |
| CRISPR knockout screen | Gene essentiality for MCFA metabolism | Identifying novel regulators |
| RNA-seq | Gene expression changes | Transcriptional response to MCFA availability |
| LC-MS metabolomics | MCFA and acyl-CoA levels | Quantifying pathway intermediates |
| Western blot | Protein expression of MCFA enzymes | Validating knockout or overexpression |
| Seahorse assay | Mitochondrial respiration | Measuring MCFA-driven oxygen consumption |
| Electro-fermentation | Microbial MCFA production | Industrial biotechnology optimization |
Metabolic Flux Analysis
Isotope tracing with 13C-labeled MCFAs can quantify their oxidation and incorporation into metabolites. This method is used to assess metabolic reprogramming in cells and tissues.
CRISPR Screening
Genome-wide CRISPR knockout screens can identify genes essential for MCFA metabolism, such as ACSM3, by selecting for cells that survive under MCFA-dependent conditions.
RNA Sequencing
Transcriptomic profiling reveals changes in expression of MCFA metabolic genes under different conditions, such as pH shifts in fermentation.
Proteomics and Metabolomics
Mass spectrometry-based proteomics and metabolomics can measure enzyme levels and MCFA species, providing a comprehensive view of pathway activity.
How CRISPR Can Be Used to Study GO:0051791 medium-chain fatty acid metabolic process
Knockout
CRISPR knockout of ACSM3 in kidney tubular cells impairs MCFA metabolism and exacerbates fibrosis in mouse models, demonstrating its causal role. Knockout of ACADM in cell lines recapitulates MCAD deficiency phenotypes.
Point Mutation
Introducing point mutations in ACADM or HADHA via CRISPR can model human fatty acid oxidation disorders and test the impact on enzyme activity and metabolic flux.
Knock-in
Knock-in of tagged ACSM3 allows for affinity purification and interactome analysis, revealing novel binding partners in MCFA metabolism.
Overexpression
Overexpression of ACSM3 or PPARA in metabolic cell lines can enhance MCFA oxidation and protect against lipid-induced stress, providing gain-of-function models.
How EDITGENE Supports medium-chain fatty acid metabolic process Research
Researchers studying medium-chain fatty acid metabolic process-related genes often need to determine whether a candidate gene is causally involved in metabolic regulation or disease. EDITGENE provides comprehensive CRISPR services to accelerate this discovery.
Contact EDITGENE today to design your custom CRISPR model for medium-chain fatty acid metabolic process research.
Frequently Asked Questions About medium-chain fatty acid metabolic process
What is medium-chain fatty acid metabolic process?
It is the set of biochemical reactions involving fatty acids with 6 to 12 carbons, including their oxidation and synthesis, as defined by GO:0051791.
What genes are involved in medium-chain fatty acid metabolism?
Key genes include ACSM3, ACADM, HADHA, CPT1A, and PPARA, among others.
How is medium-chain fatty acid metabolism regulated?
It is regulated by tissue-specific factors, pH, and transcriptional regulators like PPAR alpha.
What diseases are linked to medium-chain fatty acid metabolism?
Kidney fibrosis, obesity, and long-chain fatty acid oxidation disorders are associated with this pathway.
Why are medium-chain fatty acids important for energy?
They are rapidly oxidized and can provide energy independently of carnitine in liver and kidney.
What is the role of ACSM3 in medium-chain fatty acid metabolism?
ACSM3 activates medium-chain fatty acids, and its deficiency impairs metabolism and worsens kidney fibrosis.
Can CRISPR be used to study medium-chain fatty acid metabolism?
Yes, CRISPR knockout, knock-in, and overexpression models are powerful tools to dissect gene function in this pathway.
What is triheptanoin and how does it relate to MCFA metabolism?
Triheptanoin is a medium-chain triglyceride used to treat long-chain fatty acid oxidation disorders, approved in 2020.
How does pH affect medium-chain fatty acid production?
pH shifts can regulate metabolic pathways in fermentation, favoring MCFA synthesis.
What methods are used to study medium-chain fatty acid metabolism?
Methods include isotope tracing, CRISPR screens, RNA-seq, and metabolomics.
Conclusion
Medium-chain fatty acid metabolic process (GO:0051791) is a vital biological pathway with roles in energy homeostasis, disease, and biotechnology. Understanding its regulation and genetic components offers opportunities for therapeutic intervention and metabolic engineering. EDITGENE provides advanced CRISPR tools to study this pathway in depth.
References
- 1. Schönfeld P et al.. 2016. Short- and medium-chain fatty acids in energy metabolism: the cellular perspective.. J Lipid Res 57(6):943-54 PMID: 27080715
- 2. Li J et al.. 2025. Tubular ACSM3 deficiency impairs medium-chain fatty acid metabolism and aggravates kidney fibrosis.. Proc Natl Acad Sci U S A 122(38):e2505752122 PMID: 40953271
- 3. Wang Y et al.. 2025. pH-dependent medium-chain fatty acid synthesis in waste activated sludge fermentation: Metabolic pathway regulation.. J Environ Manage 373:123722 PMID: 39693984
- 4. Shirley M. 2020. Triheptanoin: First Approval.. Drugs 80(15):1595-1600 PMID: 32897506
- 5. Ma H et al.. 2022. Medium-chain fatty acid production from Chinese liquor brewing yellow water by electro-fermentation: Division of fermentation process and segmented electrical stimulation.. Bioresour Technol 360:127510 PMID: 35752258
- 6. Zhang L et al.. 2023. Medium-chain fatty acid production from thermal hydrolysed sludge without external electron donor supplementation.. Bioresour Technol 374:128805 PMID: 36849100
- 7. Pereyra AS et al.. 2023. Medium-chain fatty acid oxidation is independent of l-carnitine in liver and kidney but not in heart and skeletal muscle.. Am J Physiol Gastrointest Liver Physiol 325(4):G287-G294 PMID: 37461880
- 8. Papamandjaris AA et al.. 1998. Medium chain fatty acid metabolism and energy expenditure: obesity treatment implications.. Life Sci 62(14):1203-15 PMID: 9570335
